Overcoming Resistance to Targeted Therapies in Cancer

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Targeted therapies have revolutionized cancer treatment by targeting specific oncogenic drivers like BCR-ABL in chronic myeloid leukemia (CML) and HER2 in breast cancer.
• Precision medicine approaches targeting mutations such as EGFR in lung cancer and BRAF in melanoma have shown significant clinical benefits.
• Despite initial success, many patients develop disease progression within 6-12 months due to acquired resistance to targeted therapies.

Purpose of the Study:

• To discuss the identification of secondary resistance mechanisms in cancer.
• To explore how this knowledge can inform novel treatment strategies for relapsed patients.
• To highlight the application of omics-based approaches and preclinical models in understanding resistance.

Main Methods:

• Review of recent advancements in understanding oncogenic drivers and targeted therapies.
• Application of omics-based approaches (genomics, transcriptomics, etc.) to identify resistance mechanisms.
• Utilizing improved preclinical models to study drug resistance in cancer.

Main Results:

• Targeted therapies offer substantial initial responses but are often limited by acquired resistance.
• Omics-based approaches and preclinical models facilitate the rapid identification of secondary resistance mechanisms.
• Understanding resistance mechanisms enables the development of rational, novel treatment strategies.

Conclusions:

• Knowledge of resistance mechanisms is crucial for overcoming therapeutic limitations in targeted cancer therapy.
• Novel treatment strategies can be rationally designed for relapsed patients based on identified resistance mechanisms.
• Genomically selected cancer populations benefit from precision medicine approaches that address acquired resistance.